Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Future Cardiology
|
October 31, 2018
Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program
Robert M Stoekenbroek, David Kallend, Peter Lj Wijngaard, et al.
Current Opinion in Lipidology
|
July 9, 2008
The value of HDL genetics
Adriaan G Holleboom, Menno Vergeer, G Kees Hovingh, et al.
Nature Clinical Practice. Cardiovascular Medicine
|
March 12, 2008
Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis
Eric de Groot, Sander I van Leuven, Raphaël Duivenvoorden, et al.
Cardiovascular Research
|
April 4, 2020
Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
Ulf Landmesser, Arash Haghikia, Lawrence A Leiter, et al.
Journal of Hypertension
|
February 28, 2008
Haplotype of the angiotensinogen gene is associated with coronary heart disease in familial hypercholesterolemia
Jeroen B van der Net, Aaron Isaacs, Geesje M Dallinga-Thie, et al.
Journal of Clinical Lipidology
|
June 5, 2023
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial
Christie M Ballantyne, Marc Ditmarsch, John Jp Kastelein, et al.
The Journal of Prevention of Alzheimer'S Disease
|
October 18, 2025
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease
Michael H Davidson, Michael Szarek, Philip Scheltens, et al.
American Journal of Preventive Cardiology
|
July 3, 2026
Obicetrapib safety analysis: Pooled phase 3 clinical trial experience
Adam J Nelson, John Jp Kastelein, Marc Ditmarsch, et al.
American Journal of Preventive Cardiology
|
July 30, 2021
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV
Adam J Nelson, Rishi Puri, Danielle M Brennan, et al.
American Journal of Preventive Cardiology
|
August 10, 2021
Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091]
Adam J Nelson, Rishi Puri, Danielle M Brennan, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Future Cardiology
|
October 31, 2018
Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program
Robert M Stoekenbroek, David Kallend, Peter Lj Wijngaard, et al.
Current Opinion in Lipidology
|
July 9, 2008
The value of HDL genetics
Adriaan G Holleboom, Menno Vergeer, G Kees Hovingh, et al.
Nature Clinical Practice. Cardiovascular Medicine
|
March 12, 2008
Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis
Eric de Groot, Sander I van Leuven, Raphaël Duivenvoorden, et al.
Cardiovascular Research
|
April 4, 2020
Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
Ulf Landmesser, Arash Haghikia, Lawrence A Leiter, et al.
Journal of Hypertension
|
February 28, 2008
Haplotype of the angiotensinogen gene is associated with coronary heart disease in familial hypercholesterolemia
Jeroen B van der Net, Aaron Isaacs, Geesje M Dallinga-Thie, et al.
Journal of Clinical Lipidology
|
June 5, 2023
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial
Christie M Ballantyne, Marc Ditmarsch, John Jp Kastelein, et al.
The Journal of Prevention of Alzheimer'S Disease
|
October 18, 2025
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease
Michael H Davidson, Michael Szarek, Philip Scheltens, et al.
American Journal of Preventive Cardiology
|
July 3, 2026
Obicetrapib safety analysis: Pooled phase 3 clinical trial experience
Adam J Nelson, John Jp Kastelein, Marc Ditmarsch, et al.
American Journal of Preventive Cardiology
|
July 30, 2021
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV
Adam J Nelson, Rishi Puri, Danielle M Brennan, et al.
American Journal of Preventive Cardiology
|
August 10, 2021
Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091]
Adam J Nelson, Rishi Puri, Danielle M Brennan, et al.
Page
of 2